Arbutus Biopharma Corporation

Adam Judge

James Heyes

Lorne Ralph Palmer

Mark Wood

Amy C H Lee

Richard James Holland

Alan Martin

Kieu Lam

Nicholas Michael Snead

Emily P Thi

Petra Schreiner

Xin Ye

The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (e) a cationic lipid; and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid such as siRNA or mRNA to a patient (e.g. a human) or to a cell.

Lipid nanoparticle formulations

The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

Targeted compositions

Growing community of inventors

Bainbridge Island, WA, United States of America

Adam Judge